

## ORYZON Announces Expansion of its Scientific Advisory Board

### Congregates world known experts in Alzheimer's disease

**BARCELONA, SPAIN and CAMBRIDGE, MA, January 16<sup>th</sup>, 2017** – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced key additions to its Scientific Advisory Board (SAB) to reinforce the capabilities of its epigenetic drug ORY-2001 in neurodegenerative and neuroinflammatory diseases, a drug for which a Phase I clinical trial is expected to be completed this year. The new members are:

**Professor Howard Fillit, MD.**, is an internationally recognized geriatrician and neuroscientist and expert in Alzheimer's disease. He is the Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is now a clinical professor of geriatric medicine and palliative care, medicine and neuroscience at the Icahn School of Medicine. He is the author or co-author of more than 300 scientific articles, abstracts and books, including the leading international Brocklehurst's Textbook of Geriatric Medicine and Gerontology currently in its 8th edition.

**José Luis Molinuevo, PhD, MD**, is an internationally reputed neurologist specialized in AD, PD and related disorders. He was the Director of the Alzheimer's disease Unit at the Hospital Clínic of Barcelona and now he is the Scientific Director of the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation. He is a member of the European Alzheimer Disease Consortium, of the dementia panel for the European Association of Neurology, and of the Alzheimer Biomarker Standardization Initiative (ABSI). He is the Spanish coordinator of the BIOMARKAPD of the Joint Programming on Neurodegenerative Diseases, co-lead and partner of several Innovative Medicine Initiative consortiums and part of the International Working Group and the National Institute on Aging-Alzheimer's Association (NIA-AA) groups for developing new research criteria. He is principal investigator of multiple clinical trials and research studies on AD, has published over 220 international scientific papers, several books and over 20 book chapters on neurodegenerative diseases.

The Scientific Advisory Board also includes other CNS specialists: **Professor Harald Hampel**, MD a world authority on Alzheimer's disease and related neurodegenerative diseases. He is Professor and AXA Research Fund and UPMC Chair at the Sorbonne Universities, Pierre and Marie Curie University (UPMC) in Paris, France, **Professor Xavier Montalban** MD, President of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Chairman of the International Medical & Scientific Board of the Multiple Sclerosis International Federation (MSIF) and **Professor Isidro Ferrer**, MD a renowned neuropathologist and Director of the Institute of Neuropathology at the Bellvitge Hospital in Barcelona. The SAB has other members that are renowned specialists in Epigenetics and Cancer.

The SAB is functioning as a strategic network of scientific, medical and clinical experts to Oryzon as the company progresses the development of its pipeline in Epigenetics and will be in position to initiate phase II trials with its lead candidate ORY-2001 in neurodegenerative disorders in the near future.

**About ORY-2001**

ORY-2001 is a highly selective dual LSD1-MAOB inhibitor. The molecule, which focuses on cognitive decline and memory loss, has a good safety profile and therapeutic index in preclinical trials. In nontransgenic AD mouse models, long-term treatments with the drug demonstrated a marked cognitive improvement. ORY-2001 is currently in a Phase I clinical study in healthy volunteers. The company is also exploring its potential in other CNS disorders such as Multiple Sclerosis.

**About Alzheimer's disease**

Alzheimer's disease is the most common form of dementia in adults. It is estimated to affect 5.3 million Americans and over 30 million people worldwide with an average course of 8-12 years. It is projected that the disease prevalence will double over the next 20 years. Marketed products address some of the symptoms, but there are no treatments currently available. The economic cost of Alzheimer's is expected to grow in the coming years. Projections of the direct cost of Alzheimer's disease in adults over 65 could balloon to \$1.1 trillion in 2050 (in today's dollars) with a total of \$20.8 trillion in medical costs between 2015 and 2050, according to the Alzheimer's Association

**About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by +20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit [www.oryzon.com](http://www.oryzon.com).

**FORWARD-LOOKING STATEMENTS**

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This

press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

**US Contact:****The Trout Group****Maria Kelman**

+1 646 378 2932

**mkelman@troutgroup.com****Spain:****ATREVIA****Patricia Cobo/Luis Rejano**

+34 91 564 07 25

**pcobo@atrevia.com****lrejano@atrevia.com****The Company:****Anna K Baran****IR Director**

+44 (0) 752 1083 006

**abaran@oryzon.com**